| Michael J Jose, CRNA | |
|
35 Medical Center Pkwy Ste 201, Augusta, ME 04330-8160 | |
| (207) 622-1959 | |
| (207) 430-4007 |
| Full Name | Michael J Jose |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 6 Years |
| Location | 35 Medical Center Pkwy Ste 201, Augusta, Maine |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235624370 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | RNA183033 (Maine) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mid Coast Hospital | Brunswick, ME | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mainehealth | 7517860588 | 2067 |
News Archive
While much of the scientific and medical community rushes to develop therapeutic agents for COVID-19 based on clinical data, getting a better understanding of the brand-new virus remains crucial.
Abbott and Neurocrine Biosciences, Inc. today announced that they have entered into a collaboration agreement to develop and commercialize elagolix for the treatment of endometriosis-related pain. Elagolix is a novel, first-in-class oral gonadotropin-releasing hormone (GnRH) antagonist, which has recently completed a phase IIb study in endometriosis. In addition to endometriosis, elagolix will be evaluated for the treatment of uterine fibroids.
Researchers from the University of California, Davis have developed a specific and quantitative means of measuring levels of the fragile X mental retardation 1 (FMR1) protein (FMRP), which is mutated in fragile X syndrome. The related report by Iwahashi et al, "A quantitative ELISA assay for the fragile X mental retardation 1 protein," appears in the July 2009 issue of the Journal of Molecular Diagnostics.
Rachel ter Horst, medical advocacy adviser at Medecins Sans Frontieres, describes findings presented at the recent 31st biennial International Scientific Council for Trypanosomiasis Research and Control in Bamako, Mali, in this "BMJ Group Blogs" post.
› Verified 6 days ago
| Entity Name | Mainehealth |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790265502 PECOS PAC ID: 7517860588 Enrollment ID: O20040701000166 |
News Archive
While much of the scientific and medical community rushes to develop therapeutic agents for COVID-19 based on clinical data, getting a better understanding of the brand-new virus remains crucial.
Abbott and Neurocrine Biosciences, Inc. today announced that they have entered into a collaboration agreement to develop and commercialize elagolix for the treatment of endometriosis-related pain. Elagolix is a novel, first-in-class oral gonadotropin-releasing hormone (GnRH) antagonist, which has recently completed a phase IIb study in endometriosis. In addition to endometriosis, elagolix will be evaluated for the treatment of uterine fibroids.
Researchers from the University of California, Davis have developed a specific and quantitative means of measuring levels of the fragile X mental retardation 1 (FMR1) protein (FMRP), which is mutated in fragile X syndrome. The related report by Iwahashi et al, "A quantitative ELISA assay for the fragile X mental retardation 1 protein," appears in the July 2009 issue of the Journal of Molecular Diagnostics.
Rachel ter Horst, medical advocacy adviser at Medecins Sans Frontieres, describes findings presented at the recent 31st biennial International Scientific Council for Trypanosomiasis Research and Control in Bamako, Mali, in this "BMJ Group Blogs" post.
› Verified 6 days ago
| Entity Name | Kennebec Anesthesia Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992789184 PECOS PAC ID: 8325027428 Enrollment ID: O20040714000140 |
News Archive
While much of the scientific and medical community rushes to develop therapeutic agents for COVID-19 based on clinical data, getting a better understanding of the brand-new virus remains crucial.
Abbott and Neurocrine Biosciences, Inc. today announced that they have entered into a collaboration agreement to develop and commercialize elagolix for the treatment of endometriosis-related pain. Elagolix is a novel, first-in-class oral gonadotropin-releasing hormone (GnRH) antagonist, which has recently completed a phase IIb study in endometriosis. In addition to endometriosis, elagolix will be evaluated for the treatment of uterine fibroids.
Researchers from the University of California, Davis have developed a specific and quantitative means of measuring levels of the fragile X mental retardation 1 (FMR1) protein (FMRP), which is mutated in fragile X syndrome. The related report by Iwahashi et al, "A quantitative ELISA assay for the fragile X mental retardation 1 protein," appears in the July 2009 issue of the Journal of Molecular Diagnostics.
Rachel ter Horst, medical advocacy adviser at Medecins Sans Frontieres, describes findings presented at the recent 31st biennial International Scientific Council for Trypanosomiasis Research and Control in Bamako, Mali, in this "BMJ Group Blogs" post.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael J Jose, CRNA 35 Medical Center Pkwy Ste 201, Augusta, ME 04330-8160 Ph: (207) 622-1959 | Michael J Jose, CRNA 35 Medical Center Pkwy Ste 201, Augusta, ME 04330-8160 Ph: (207) 622-1959 |
News Archive
While much of the scientific and medical community rushes to develop therapeutic agents for COVID-19 based on clinical data, getting a better understanding of the brand-new virus remains crucial.
Abbott and Neurocrine Biosciences, Inc. today announced that they have entered into a collaboration agreement to develop and commercialize elagolix for the treatment of endometriosis-related pain. Elagolix is a novel, first-in-class oral gonadotropin-releasing hormone (GnRH) antagonist, which has recently completed a phase IIb study in endometriosis. In addition to endometriosis, elagolix will be evaluated for the treatment of uterine fibroids.
Researchers from the University of California, Davis have developed a specific and quantitative means of measuring levels of the fragile X mental retardation 1 (FMR1) protein (FMRP), which is mutated in fragile X syndrome. The related report by Iwahashi et al, "A quantitative ELISA assay for the fragile X mental retardation 1 protein," appears in the July 2009 issue of the Journal of Molecular Diagnostics.
Rachel ter Horst, medical advocacy adviser at Medecins Sans Frontieres, describes findings presented at the recent 31st biennial International Scientific Council for Trypanosomiasis Research and Control in Bamako, Mali, in this "BMJ Group Blogs" post.
› Verified 6 days ago
Stacey C Dostie, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 35 Medical Center Pkwy, Augusta, ME 04330 Phone: 207-622-1959 Fax: 207-430-4007 | |
Vanessa Railton, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 35 Medical Center Pkwy, Augusta, ME 04330 Phone: 207-622-1959 Fax: 207-430-4007 | |
Elisha Rose Coppens, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 35 Medical Center Pkwy # Pa, Augusta, ME 04330 Phone: 207-622-1959 Fax: 207-430-4007 | |
Sharon A Paradis, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 6 E Chestnut St, Augusta, ME 04330 Phone: 207-622-1959 Fax: 207-622-1959 | |
Ms. Edith June St. Pierre, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 1 Va Ctr, Augusta, ME 04330 Phone: 207-623-8411 Fax: 207-621-4890 | |
Dana Jo Marshall, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 35 Medical Center Pkwy, Ste 201, Augusta, ME 04330 Phone: 207-622-1959 Fax: 207-430-4007 |